NASDAQ:ZGNX

Zogenix Stock Forecast, Price & News

$15.06
-0.11 (-0.73 %)
(As of 09/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.66
$15.15
50-Day Range
$13.11
$18.00
52-Week Range
$13.01
$23.86
Volume391,578 shs
Average Volume830,417 shs
Market Capitalization$841.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
30 days | 90 days | 365 days | Advanced Chart
Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.


Zogenix logo

About Zogenix

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

263rd out of 1,352 stocks

Pharmaceutical Preparations Industry

128th out of 665 stocks

Analyst Opinion: 4.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

Is Zogenix a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix
or view top-rated stocks.

What stocks does MarketBeat like better than Zogenix?

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zogenix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings data on Thursday, August, 5th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.93) by $0.12. The company had revenue of $18.79 million for the quarter, compared to analyst estimates of $17.06 million. Zogenix had a negative trailing twelve-month return on equity of 68.36% and a negative net margin of 558.42%.
View Zogenix's earnings history
.

How has Zogenix's stock been impacted by COVID-19 (Coronavirus)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZGNX shares have decreased by 33.6% and is now trading at $15.06.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZGNX?

6 Wall Street analysts have issued 1-year price objectives for Zogenix's shares. Their forecasts range from $17.67 to $64.00. On average, they expect Zogenix's share price to reach $34.28 in the next year. This suggests a possible upside of 127.6% from the stock's current price.
View analysts' price targets for Zogenix
or view top-rated stocks among Wall Street analysts.

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Stephen James Farr, President, Chief Executive Officer & Director
  • Ashish M. Sagrolikar, Chief Operating Officer & Executive Vice President
  • Michael Patrick Smith, Chief Financial Officer, Treasurer & Executive VP
  • Bradley S. Galer, Chief Medical Officer & Executive Vice President
  • Steven A. Johnson, Vice President, Legal Council & Compliance Office

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.17%), Morgan Stanley (7.39%), Morgan Stanley (7.39%), Vanguard Group Inc. (7.26%), Cadian Capital Management LP (5.68%) and Franklin Resources Inc. (5.46%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Federated Hermes Inc., Woodline Partners LP, Deutsche Bank AG, Healthcare of Ontario Pension Plan Trust Fund, Squarepoint Ops LLC, Nantahala Capital Management LLC, and Rice Hall James & Associates LLC.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

Which institutional investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Fairmount Funds Management LLC, Morgan Stanley, Morgan Stanley, Franklin Resources Inc., Balyasny Asset Management LLC, Renaissance Technologies LLC, and Kettle Hill Capital Management LLC. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Mark C Wiggins, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix
or or view top insider-buying stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $15.06.

How much money does Zogenix make?

Zogenix has a market capitalization of $841.82 million and generates $13.64 million in revenue each year. The company earns $-209,380,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 218 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

Where are Zogenix's headquarters?

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at (510) 550-8300 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.